The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

As per The Business Research Company’s Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2023, The global chronic myeloid leukemia (CML) treatment market is expected to grow from $7.33 billion in 2022 to $7.73 billion in 2023 at a compound annual growth rate (CAGR) of 5.45%. The chronic myeloid leukemia (CML) treatment market is expected to reach $9.70 billion in 2027 at a CAGR of 5.82%.

What was the major driver in the chronic myeloid leukemia (CML) treatment market?
The rising incidence and prevalence of chronic myeloid leukemia (CML) population is expected to propel the growth of the chronic myeloid leukemia (CML) treatment market going forward. Chronic myeloid leukemia also known as chronic myelogenous leukemia, is a type of cancer that affects the bone marrow and blood. It is characterized by the overproduction of immature white blood cells called myeloid cells. Chronic myeloid leukemia (CML) treatment helps to slow the progression of cancer and stop it from reaching an advanced phase. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, in 2023, around 35,730 persons (19,860 men and 15,870 women) are anticipated to receive a multiple myeloma diagnosis and 12,590 deaths from this illness are anticipated in 2023 (7,000 males and 5,590 women). Therefore, the rising incidence and prevalence of chronic myeloid leukemia (CML) population is driving the growth of the chronic myeloid leukemia (CML) treatment market going forward.

View More On The Chronic Myeloid Leukemia (CML) Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

What was the key trend in the chronic myeloid leukemia (CML) treatment market?
Product Innovation is a key trend gaining popularity in the chronic myeloid leukemia (CML) treatment market. Companies operating in the chronic myeloid leukemia (CML) treatment market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Novartis, a Switzerland-based multinational pharmaceutical corporation, announced FDA (Foods and Drugs Association) approval of Scemblix (asciminib) for the treatment of chronic myeloid leukemia. Scemblix is the first FDA-approved CML treatment. Scemblix works by binding to the ABL myristoyl pocket and is used to treat patients who experience resistance and, or intolerance to currently available TKI therapies1-3. At 24 weeks, Scemblix outperformed Bosulif (bosutinib) in terms of major molecular response (MMR) rate (25% vs. 13%) and more than three times lower discontinuation rates due to adverse effects (7% vs. 25%).

Which was the largest region in the chronic myeloid leukemia (CML) treatment market?
North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2022. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the chronic myeloid leukemia (CML) treatment market prominent players?
Major players in the chronic myeloid leukemia (cml) treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hospira Inc., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Stragen Pharma SA, Orca Bio, and Bio-Path Holdings Inc.

Key chronic myeloid leukemia (CML) treatment market segments
The global chronic myeloid leukemia (CML) treatment market is segmented –
1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types
3) By Application: Hospitals, Clinic, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Request A Sample Of The Global Chronic Myeloid Leukemia (CML) Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12084&type=smp

The Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2023  provides a comprehensive overview on the chronic myeloid leukemia (CML) treatment market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Leukemia Therapeutics Global Market Report 2023
Peripheral Vascular Devices And Equipment Global Market Report 2023
Tyrosine Kinase Inhibitors Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model